HBOT Research

  1. Home
  2. HBOT Research

Explore our database on Hyperbaric Oxygen Therapy (HBOT) Research below.

Extivita maintains an extensive research & publication database for various diseases and therapies such as Hyperbaric Oxygen Therapy, Neurofeedback, Nutritional IV Therapy, Infrared Sauna, and Pulsed Electromagnetic Field Therapy.

For a complete list of indications treated at Extivita, explore the conditions we treat.

 

A favourable response to surgical intervention and hyperbaric oxygen therapy in pyoderma gangrenosum.

Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterised with ulcerations. Inflammatory bowel diseases (ulcerative colitis and Crohn’s disease) and haematologic diseases (leukaemia, preleukaemia and monoclonal gammopathy) have been reported in about 40-50% of PG patients in whom the treatment of the underlying disease is important for the improvement of the lesions. We herein report a colorectal adenocarcinoma patient with PG, who responded partially to topical treatments and systemic immunosuppressants and healed completely with the aid of surgical wound repair and hyperbaric oxygen therapy.

read more

Hyperbaric medicine for the hospital-based physician.

Abstract: Hyperbaric oxygen (HBO2) is the inhalation of 100% oxygen at pressures > 1.4 times atmospheric pressure. Hyperbaric oxygen can be delivered in monoplace (single person) or multiplace (multi-person) chambers. Most clinical HBO2 exposures are between 2 and 2.4...

read more

Hyperbaric oxygen and Ginkgo Biloba extract inhibit Aฮฒ25-35-induced toxicity and oxidative stress in vivo: a potential role in Alzheimer’s disease.

Alzheimer’s disease is characterized by the accumulation and deposition of Aฮฒ peptides in human brains and Aฮฒ induced free radical-mediated damage is one of the hypotheses. In the present study, we explored the protective effects of hyperbaric oxygen (HBO) and Ginkgo Biloba extract (EGB761) on Aฮฒ25-35-induced brain toxicity. Our results demonstrated that EGB761, HBO, and the combination HBO and EGB761, could significantly improve the cognitive function in AD rats’ model, especially the combination group. What’s more, the activities of superoxide dismutase (SOD) in rat hippocampal tissue were obviously enhanced followed by evidently reduced malondialdehyde (MDA) levels in the same treatment groups mentioned earlier. There were no differences of nitric oxide (NO) productions in the group of EGB761, HBO, and HBO and EGB761, but they were all lower than that of model group. These findings suggest that both HBO and EGB761 may relieve cell toxicity and oxidative stress in AD and thus play a potential protective role in AD. Furthermore, the combination could have better effects compared with single one.

read more